An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC. “At this analysis ...